How Generative AI is Unlocking Cost Savings, Supply Chain Security, and Strategic Synergies
The healthcare industry is at a turning point. With rising costs, aging populations, and increasingly complex supply chains, companies in pharmaceuticals, medtech, and healthcare services must find new ways to optimize procurement, manage risks, and drive efficiencies.
From securing Active Pharmaceutical Ingredient (API) supply chains to optimizing costs and enabling data-driven negotiations, AI-powered tools are giving procurement teams the insights they need to make faster, smarter, and more strategic decisions.
Want to stay ahead in healthcare procurement? Download the latest issue of our Supply Management Insights magazine to explore how GenAI is reshaping the industry and creating new opportunities.
What can you take away from this issue?
GenAI in Healthcare: A Game Changer for Procurement
- How AI-powered tools shift procurement from reactive to proactive management.
- Why leading healthcare companies are investing in GenAI to improve efficiency, cost control, and supply chain resilience.
How to gain efficiency in different healthcare sectors
- Unlocking Synergies in Healthcare Mergers
- Securing API Supply Chains with AI-Powered Risk Management
- Fact-Based Negotiations with AI-Powered Cost Models
The Future of AI in Healthcare Procurement
The future of AI in healthcare procurement is promising, with Generative AI unlocking hidden savings that can be reinvested in research and development—driving innovation and ensuring long-term competitive advantage. By enhancing transparency and resilience in supply chains, AI is reducing inefficiencies and enabling smarter procurement decisions. Early adopters stand to gain a significant edge, making now the ideal time to implement AI-driven solutions and stay ahead in an evolving industry.
- AI in Procurement: How GenAI cuts through the complexity
- Experts on AI: Melih Yener (BCGX)
- Generative AI in the Healthcare Sector: Unveiling New Opportunities
- Pick up speed: Optimizing indirect spend with GenAI
- Untapped potential for Private Equity: From barriers to breakthroughs – Unleashing GenAI across portfolios
- INVERTO Office Paris: Interview with Isabelle Pinto Carradine
Fill out the contact form to receive the magazine issue. You will then receive the entire issue by e-mail.
// Preview | Table of contents & editorial
Authors
Nicolas Willmann
Managing Director
is a Managing Director at Inverto in Cologne and responsible for our Healthcare business, advising clients on transformation projects, cost-down programs, and mergers & acquisitions.
Sabrina Morton
Principal
is a Principal at Inverto in London, specializing in biopharma companies and complex transformation projects, including procurement model redesign.